Mechanisms and functions of agonist-independent activation in the angiotensin II type 1 receptor

Molecular and Cellular Endocrinology

Volumn 302, Issue 2, 2009, Pages 140-147

  Akazawa, Hiroshi ^a   Yasuda, Noritaka ^a   Komuro, Issei ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiac hypertrophy; G protein coupled receptor; Inverse agonist; Mechanical stress; Receptor conformation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR;

ATHEROSCLEROSIS; CONFORMATIONAL TRANSITION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERINSULINEMIA; MECHANICAL STRESS; MOLECULAR DYNAMICS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

HUMANS; PROTEIN CONFORMATION; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; STRESS, MECHANICAL;

EID: 62949206286     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.11.007     Document Type: Review

References (97)

1. Balmforth A.J., Lee A.J., Warburton P., Donnelly D., and Ball S.G. The conformational change responsible for AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII. J. Biol. Chem. 272 (1997) 4245-4251
2. Bendig G., Grimmler M., Huttner I.G., Wessels G., Dahme T., Just S., Trano N., Katus H.A., Fishman M.C., and Rottbauer W. Integrin-linked kinase, a novel component of the cardiac mechanical stretch sensor, controls contractility in the zebrafish heart. Genes Dev. 20 (2006) 2361-2372
3. Billet S., Bardin S., Verp S., Baudrie V., Michaud A., Conchon S., Muffat-Joly M., Escoubet B., Souil E., Hamard G., Bernstein K.E., Gasc J.M., Elghozi J.L., Corvol P., and Clauser E. Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. J. Clin. Invest. 117 (2007) 1914-1925
4. Bond R.A., and Ijzerman A.P. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol. Sci. 27 (2006) 92-96
5. Boucard A.A., Roy M., Beaulieu M.E., Lavigne P., Escher E., Guillemette G., and Leduc R. Constitutive activation of the angiotensin II type 1 receptor alters the spatial proximity of transmembrane 7 to the ligand-binding pocket. J. Biol. Chem. 278 (2003) 36628-36636
6. Brancaccio M., Fratta L., Notte A., Hirsch E., Poulet R., Guazzone S., De Acetis M., Vecchione C., Marino G., Altruda F., Silengo L., Tarone G., and Lembo G. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat. Med. 9 (2003) 68-75
7. Chachisvilis M., Zhang Y.L., and Frangos J.A. G protein-coupled receptors sense fluid shear stress in endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 15463-15468
8. Chen S., Lin F., Xu M., and Graham R.M. Phe(303) in TMVI of the alpha(1B)-adrenergic receptor is a key residue coupling TM helical movements to G-protein activation. Biochemistry 41 (2002) 588-596
9. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Kuhn P., Weis W.I., Kobilka B.K., and Stevens R.C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318 (2007) 1258-1265
10. Costa T., and Cotecchia S. Historical review: Negative efficacy and the constitutive activity of G-protein-coupled receptors. Trends Pharmacol. Sci. 26 (2005) 618-624
11. Costa T., and Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 7321-7325
12. Cotecchia S., Exum S., Caron M.G., and Lefkowitz R.J. Regions of the alpha 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 2896-2900
13. Davies E., Bonnardeaux A., Plouin P.F., Corvol P., and Clauser E. Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma. J. Clin. Endocrinol. Metab. 82 (1997) 611-615
14. Dragun D., Muller D.N., Brasen J.H., Fritsche L., Nieminen-Kelha M., Dechend R., Kintscher U., Rudolph B., Hoebeke J., Eckert D., Mazak I., Plehm R., Schonemann C., Unger T., Budde K., Neumayer H.H., Luft F.C., and Wallukat G. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 352 (2005) 558-569
15. Farrens D.L., Altenbach C., Yang K., Hubbell W.L., and Khorana H.G. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274 (1996) 768-770
16. Feng Y.H., Noda K., Saad Y., Liu X.P., Husain A., and Karnik S.S. The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. J. Biol. Chem. 270 (1995) 12846-12850
17. Feng Y.H., Miura S., Husain A., and Karnik S.S. Mechanism of constitutive activation of the AT1 receptor: influence of the size of the agonist switch binding residue Asn(111). Biochemistry 37 (1998) 15791-15798
18. Fierens F.L., Vanderheyden P.M., De Backer J.P., and Vauquelin G. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding. Eur. J. Pharmacol. 372 (1999) 199-206
19. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21 (2000) 90-113
20. Gether U., and Kobilka B.K. G protein-coupled receptors. II. Mechanism of agonist activation. J. Biol. Chem. 273 (1998) 17979-17982
21. Griendling K.K., Lassegue B., and Alexander R.W. Angiotensin receptors and their therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 36 (1996) 281-306
22. Groblewski T., Maigret B., Larguier R., Lombard C., Bonnafous J.C., and Marie J. Mutation of Asn111 in the third transmembrane domain of the AT1A angiotensin II receptor induces its constitutive activation. J. Biol. Chem. 272 (1997) 1822-1826
23. Hein L., Stevens M.E., Barsh G.S., Pratt R.E., Kobilka B.K., and Dzau V.J. Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 6391-6396
24. Hunyady L., and Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol. Endocrinol. 20 (2006) 953-970
25. Hunyady L., Vauquelin G., and Vanderheyden P. Agonist induction and conformational selection during activation of a G-protein-coupled receptor. Trends Pharmacol. Sci. 24 (2003) 81-86
26. Jessup M., and Brozena S. Heart failure. N. Engl. J. Med. 348 (2003) 2007-2018
27. Jongejan A., Bruysters M., Ballesteros J.A., Haaksma E., Bakker R.A., Pardo L., and Leurs R. Linking agonist binding to histamine H1 receptor activation. Nat. Chem. Biol. 1 (2005) 98-103
28. Kim S., and Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev. 52 (2000) 11-34
29. Kira Y., Kochel P.J., Gordon E.E., and Morgan H.E. Aortic perfusion pressure as a determinant of cardiac protein synthesis. Am. J. Physiol. 246 (1984) C247-C258
30. Kjeldsen S.E., Dahlof B., Devereux R.B., Julius S., Aurup P., Edelman J., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristianson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Snapinn S., and Wedel H. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan intervention for endpoint reduction (LIFE) substudy. JAMA 288 (2002) 1491-1498
31. Kjelsberg M.A., Cotecchia S., Ostrowski J., Caron M.G., and Lefkowitz R.J. Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J. Biol. Chem. 267 (1992) 1430-1433
32. Klingbeil A.U., Schneider M., Martus P., Messerli F.H., and Schmieder R.E. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 115 (2003) 41-46
33. Knoll R., Hoshijima M., Hoffman H.M., Person V., Lorenzen-Schmidt I., Bang M.L., Hayashi T., Shiga N., Yasukawa H., Schaper W., McKenna W., Yokoyama M., Schork N.J., Omens J.H., McCulloch A.D., Kimura A., Gregorio C.C., Poller W., Schaper J., Schultheiss H.P., and Chien K.R. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 111 (2002) 943-955
34. Komuro I., and Yazaki Y. Control of cardiac gene expression by mechanical stress. Annu. Rev. Physiol. 55 (1993) 55-75
35. Kung C. A possible unifying principle for mechanosensation. Nature 436 (2005) 647-654
36. Le M.T., Vanderheyden P.M., Szaszak M., Hunyady L., Kersemans V., and Vauquelin G. Peptide and nonpeptide antagonist interaction with constitutively active human AT1 receptors. Biochem. Pharmacol. 65 (2003) 1329-1338
37. Lemaire K., Van de Velde S., Van Dijck P., and Thevelein J.M. Glucose and sucrose act as agonist and mannose as antagonist ligands of the G protein-coupled receptor Gpr1 in the yeast Saccharomyces cerevisiae. Mol. Cell 16 (2004) 293-299
38. Leurs R., Smit M.J., Alewijnse A.E., and Timmerman H. Agonist-independent regulation of constitutively active G-protein-coupled receptors. Trends Biochem. Sci. 23 (1998) 418-422
39. Mann D.L., Kent R.L., and Cooper G.t. Load regulation of the properties of adult feline cardiocytes: growth induction by cellular deformation. Circ. Res. 64 (1989) 1079-1090
40. Martin S.S., Holleran B.J., Escher E., Guillemette G., and Leduc R. Activation of the angiotensin II type 1 receptor leads to movement of the sixth transmembrane domain: analysis by the substituted cysteine accessibility method. Mol. Pharmacol. 72 (2007) 182-190
41. Milligan G. Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol. Pharmacol. 64 (2003) 1271-1276
42. Miura S., and Karnik S.S. Constitutive activation of angiotensin II type 1 receptor alters the orientation of transmembrane Helix-2. J. Biol. Chem. 277 (2002) 24299-24305
43. Miura S., Feng Y.H., Husain A., and Karnik S.S. Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J. Biol. Chem. 274 (1999) 7103-7110
44. Miura S., Saku K., and Karnik S.S. Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens. Res. 26 (2003) 937-943
45. Miura S., Zhang J., Boros J., and Karnik S.S. TM2-TM7 interaction in coupling movement of transmembrane helices to activation of the angiotensin II type-1 receptor. J. Biol. Chem. 278 (2003) 3720-3725
46. Miura S., Fujino M., Hanzawa H., Kiya Y., Imaizumi S., Matsuo Y., Tomita S., Uehara Y., Karnik S.S., Yanagisawa H., Koike H., Komuro I., and Saku K. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J. Biol. Chem. 281 (2006) 19288-19295
47. Miura S., Kiya Y., Kanazawa T., Imaizumi S., Fujino M., Matsuo Y., Karnik S.S., and Saku K. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol. Endocrinol. 22 (2008) 139-146
48. Morisset S., Rouleau A., Ligneau X., Gbahou F., Tardivel-Lacombe J., Stark H., Schunack W., Ganellin C.R., Schwartz J.C., and Arrang J.M. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408 (2000) 860-864
49. Murakami M., and Kouyama T. Crystal structure of squid rhodopsin. Nature 453 (2008) 363-367
50. Nickenig G., Jung O., Strehlow K., Zolk O., Linz W., Scholkens B.A., and Bohm M. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am. J. Physiol. 272 (1997) H2701-H2707
51. Nickenig G., Roling J., Strehlow K., Schnabel P., and Bohm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 98 (1998) 2453-2460
52. Nickenig G., Strehlow K., Wassmann S., Baumer A.T., Albory K., Sauer H., and Bohm M. Differential effects of estrogen and progesterone on AT(1) receptor gene expression in vascular smooth muscle cells. Circulation 102 (2000) 1828-1833
53. Noda M., Shibouta Y., Inada Y., Ojima M., Wada T., Sanada T., Kubo K., Kohara Y., Naka T., and Nishikawa K. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem. Pharmacol. 46 (1993) 311-318
54. Noda K., Saad Y., and Karnik S.S. Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. J. Biol. Chem. 270 (1995) 28511-28514
55. Noda K., Saad Y., Kinoshita A., Boyle T.P., Graham R.M., Husain A., and Karnik S.S. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J. Biol. Chem. 270 (1995) 2284-2289
56. Noda K., Feng Y.H., Liu X.P., Saad Y., Husain A., and Karnik S.S. The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 35 (1996) 16435-16442
57. Okin P.M., Devereux R.B., Jern S., Kjeldsen S.E., Julius S., Nieminen M.S., Snapinn S., Harris K.E., Aurup P., Edelman J.M., Wedel H., Lindholm L.H., and Dahlof B. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292 (2004) 2343-2349
58. Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am. J. Hypertens. 13 (2000) 18S-24S
59. Orr A.W., Helmke B.P., Blackman B.R., and Schwartz M.A. Mechanisms of mechanotransduction. Dev. Cell 10 (2006) 11-20
60. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le Trong I., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., and Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000) 739-745
61. Paradis P., Dali-Youcef N., Paradis F.W., Thibault G., and Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 931-936
62. Park J.H., Scheerer P., Hofmann K.P., Choe H.W., and Ernst O.P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454 (2008) 183-188
63. Parma J., Duprez L., Van Sande J., Cochaux P., Gervy C., Mockel J., Dumont J., and Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365 (1993) 649-651
64. Parnot C., Miserey-Lenkei S., Bardin S., Corvol P., and Clauser E. Lessons from constitutively active mutants of G protein-coupled receptors. Trends Endocrinol. Metab. 13 (2002) 336-343
65. Paul M., Poyan Mehr A., and Kreutz R. Physiology of local renin-angiotensin systems. Physiol. Rev. 86 (2006) 747-803
66. Perez D.M., and Karnik S.S. Multiple signaling States of G-protein-coupled receptors. Pharmacol. Rev. 57 (2005) 147-161
67. Perozo E., Cortes D.M., Sompornpisut P., Kloda A., and Martinac B. Open channel structure of MscL and the gating mechanism of mechanosensitive channels. Nature 418 (2002) 942-948
68. Rasmussen S.G., Choi H.J., Rosenbaum D.M., Kobilka T.S., Thian F.S., Edwards P.C., Burghammer M., Ratnala V.R., Sanishvili R., Fischetti R.F., Schertler G.F., Weis W.I., and Kobilka B.K. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450 (2007) 383-387
69. Re R.N. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 1 (2004) 42-47
70. Ren Q., Kurose H., Lefkowitz R.J., and Cotecchia S. Constitutively active mutants of the alpha 2-adrenergic receptor. J. Biol. Chem. 268 (1993) 16483-16487
71. Rosenbaum D.M., Cherezov V., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Yao X.J., Weis W.I., Stevens R.C., and Kobilka B.K. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318 (2007) 1266-1273
72. Sachse R., Shao X.J., Rico A., Finckh U., Rolfs A., Reincke M., and Hensen J. Absence of angiotensin II type 1 receptor gene mutations in human adrenal tumors. Eur. J. Endocrinol. 137 (1997) 262-266
73. Sadoshima J., and Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu. Rev. Physiol. 59 (1997) 551-571
74. Sadoshima J., Xu Y., Slayter H.S., and Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75 (1993) 977-984
75. Samama P., Cotecchia S., Costa T., and Lefkowitz R.J. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268 (1993) 4625-4636
76. Sasamura H., Nakazato Y., Hayashida T., Kitamura Y., Hayashi M., and Saruta T. Regulation of vascular type 1 angiotensin receptors by cytokines. Hypertension 30 (1997) 35-41
77. Sawada Y., Tamada M., Dubin-Thaler B.J., Cherniavskaya O., Sakai R., Tanaka S., and Sheetz M.P. Force sensing by mechanical extension of the Src family kinase substrate p130Cas. Cell 127 (2006) 1015-1026
78. Shenker A., Laue L., Kosugi S., Merendino Jr. J.J., Minegishi T., and Cutler Jr. G.B. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 365 (1993) 652-654
79. Sodhi C.P., Kanwar Y.S., and Sahai A. Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H846-H852
80. Strange P.G. Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol. Sci. 23 (2002) 89-95
81. Takezako T., Gogonea C., Saad Y., Noda K., and Karnik S.S. Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists. J. Biol. Chem. 279 (2004) 15248-15257
82. Tanimoto K., Sugiyama F., Goto Y., Ishida J., Takimoto E., Yagami K., Fukamizu A., and Murakami K. Angiotensinogen-deficient mice with hypotension. J. Biol. Chem. 269 (1994) 31334-31337
83. Thway T.M., Shlykov S.G., Day M.C., Sanborn B.M., Gilstrap III L.C., Xia Y., and Kellems R.E. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 110 (2004) 1612-1619
84. Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carini D.J., Lee R.J., Wexler R.R., Saye J.A., and Smith R.D. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45 (1993) 205-251
85. Vanderheyden P.M., Fierens F.L., De Backer J.P., Fraeyman N., and Vauquelin G. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors. Br. J. Pharmacol. 126 (1999) 1057-1065
86. Vauquelin G., Van Liefde I., and Vanderheyden P. Models and methods for studying insurmountable antagonism. Trends Pharmacol. Sci. 23 (2002) 514-518
87. Vilardaga J.P., Steinmeyer R., Harms G.S., and Lohse M.J. Molecular basis of inverse agonism in a G protein-coupled receptor. Nat. Chem. Biol. 1 (2005) 25-28
88. Wassmann S., and Nickenig G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J. Hypertens. Suppl. 24 (2006) S15-21
89. Wassmann S., Stumpf M., Strehlow K., Schmid A., Schieffer B., Bohm M., and Nickenig G. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ. Res. 94 (2004) 534-541
90. White D.E., Coutu P., Shi Y.F., Tardif J.C., Nattel S., St. Arnaud R., Dedhar S., and Muller W.J. Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. Genes Dev. 20 (2006) 2355-2360
91. Yamano Y., Ohyama K., Chaki S., Guo D.F., and Inagami T. Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site directed mutagenesis. Biochem. Biophys. Res. Commun. 187 (1992) 1426-1431
92. Yamazaki T., Komuro I., Kudoh S., Zou Y., Shiojima I., Mizuno T., Takano H., Hiroi Y., Ueki K., and Tobe K. Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ. Res. 77 (1995) 258-265
93. Yamazaki T., Komuro I., Kudoh S., Zou Y., Shiojima I., Hiroi Y., Mizuno T., Maemura K., Kurihara H., Aikawa R., Takano H., and Yazaki Y. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J. Biol. Chem. 271 (1996) 3221-3228
94. Yasuda N., Miura S., Akazawa H., Tanaka T., Qin Y., Kiya Y., Imaizumi S., Fujino M., Ito K., Zou Y., Fukuhara S., Kunimoto S., Fukuzaki K., Sato T., Ge J., Mochizuki N., Nakaya H., Saku K., and Komuro I. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep. 9 (2008) 179-186
95. Zaman M.A., Oparil S., and Calhoun D.A. Drugs targeting the renin-angiotensin-aldosterone system. Nat. Rev. Drug Discov. 1 (2002) 621-636
96. Zou Y., Komuro I., Yamazaki T., Kudoh S., Uozumi H., Kadowaki T., and Yazaki Y. Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy. J. Biol. Chem. 274 (1999) 9760-9770
97. Zou Y., Akazawa H., Qin Y., Sano M., Takano H., Minamino T., Makita N., Iwanaga K., Zhu W., Kudoh S., Toko H., Tamura K., Kihara M., Nagai T., Fukamizu A., Umemura S., Iiri T., Fujita T., and Komuro I. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat. Cell Biol. 6 (2004) 499-506